Corticosteroids in Crohn's disease

American Journal of Gastroenterology

Volumn 97, Issue 4, 2002, Pages 803-823

  Yang, Yu Xiao ^a   Lichtenstein, Gary R ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ACNE; ANTIINFLAMMATORY ACTIVITY; BONE DENSITY; CELL ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INHIBITION KINETICS; META ANALYSIS; MOON FACE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CROHN DISEASE; HUMANS; REMISSION INDUCTION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 0036120198     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)03952-7     Document Type: Review

References (142)

1. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease
2. Management of corticosteroid-dependent and corticosteroid-refractory Crohn's disease
3. How to do without steroids in inflammatory bowel disease
4. Glucocorticosteroid action on the immune system: Molecular and cellular aspects
5. Anti-inflammatory actions of steroids: Molecular mechanisms
6. Modulation by cytokines of glucocorticoid action
7. Nuclear factor-kappa B
8. Activation of nuclear factor kappa B inflammatory bowel disease
9. Medical therapy for inflammatory bowel disease
10. Nuclear factor-kB repression in antiinflammation and immunosuppression by glucocorticoids
11. Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone
12. Lipocortin
13. Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines
14. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases
15. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression
16. Function and activation of NF-kappa B in the immune system
17. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors
18. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
19. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
20. Effect of corticosteroids on the human monocyte IgG and complement receptors
21. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy
22. Adhesion molecules in rheumatoid arthritis: Role in the pathogenesis and prospects for therapy
23. Suppression of intestinal mucosal natural killer cells by corticosteroids
24. Vasocortin: A novel glucocorticoid-induced anti-inflammatory protein
25. Inflammatory bowel disease
26. Corticosteroids and corticotrophin in the treatment of Crohn's disease
27. Long-term corticosteroid therapy for regional enteritis: An analysis of 58 courses in 54 patients
28. Corticosteroid or corticotrophin therapy in Crohn's disease (regional enteritis)
29. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
30. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
31. National Cooperative Crohn's Disease Study: Results of drug treatment
32. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
33. Frequency of glucocorticoid resistance and dependency in Crohn's disease
34. Clinical pattern of corticosteroid dependent Crohn's disease
35. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone
36. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease
37. Low dose steroids and clinical relapse in Crohn's disease: A controlled trial
38. The possible utility of steroids in the prevention of relapses of Crohn's disease in remission. A preliminary study
39. Corticosteroids for maintaining remission of Crohn's disease
40. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
41. Influence of corticosteroid treatment duration in patients with active Crohn's disease
42. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus
43. Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment
44. Predicting outcome in severe ulcerative colitis
45. Glucocorticoid resistance in asthma
46. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
47. Glucocorticoids, lipocortins and the immune response
48. Steroid-resistant asthma: Immunologic and pharmacologic features
49. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: Potential regulation of the glucocorticoid receptor
50. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta
51. The glucocorticoid insensitivity syndrome
52. The steroid resistance of Crohn's disease
53. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
54. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma
55. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers
56. Response to glucocorticoid treatment in rheumatoid arthritis: In vitro cell mediated immune assay predicts in vivo responses
57. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival
58. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes
59. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever, and certain other conditions: Study in clinical physiology
60. Minimizing complications from systemic glucocorticosteroid use
61. Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy
62. Alternate-day prednisone therapy. Evaluation of delayed hyper-sensitivity responses, control of disease and steroid side effects
63. Studies on an intermittent corticosteroid dosage regimen
64. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
65. Osteoporosis in patients with inflammatory bowel disease
66. Consequence of reduced absorption: Stone and bone disease
67. Effect of experimental colitis on bone metabolism in the rat
68. Reduced bone density in patients with inflammatory bowel disease
69. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis
70. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis
71. A controlled study of bone mineral density in patients with inflammatory bowel disease
72. Use of oral corticosteroids in the United Kingdom
73. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy
74. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study
75. Bone loss in response to long-term glucocorticoid therapy
76. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
77. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone
78. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation
79. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease
80. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
81. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
82. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease
83. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines
84. Steroid myopathy: Incidence and detection in a population with asthma
85. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma
86. Pathologic changes and contractile properties of the diaphragm in corticosteroid myopathy in hamsters: Comparison to peripheral muscle
87. Histological and histochemical changes in the muscles of rabbits given the corticosteroid triamcinolone
88. Steroid myopathy in connective tissue disease
89. Principles of the use of glucocorticosteroids in the growing child
90. Risk of infectious complications in patients taking glucocorticosteroids
91. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone
92. Side effects of glucocorticoid therapy
93. Glucocorticosteroids
94. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy
95. Corticosteroid-associated complications in elderly Crohn's disease patients
96. Does long-term low-dose corticosteroid therapy cause hypertension?
97. Glucocorticoid medication, memory and steroid psychosis in medical illness
98. The psychiatric side effects of corticosteroids
99. Presentation of the steroid psychoses
100. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature
101. Acute adverse reactions to prednisone in relation to dosage
102. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis
103. Corticosteroid-induced cataracts
104. Overview of newer glucocorticosteroid preparation for inflammatory bowel disease
105. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids
106. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsule
107. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis
108. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control
109. Comparative trial of budesonide and methylprednisolone enemas in the treatment of ulcerative colitis
110. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study
111. Oral budesonide in active ileocecal Crohn's disease - A pilot trial with a topically acting steroid
112. Oral budesonide in active Crohn's disease: An initial experience
113. A comparison of budesonide and mesalamine for active Crohn's disease
114. A comparison of budesonide with prednisolone for active Crohn's disease
115. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease
116. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
117. Budesonide versus prednisone in the treatment of active Crohn's disease
118. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease
119. Oral budesonide for active Crohn's disease
120. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study
121. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
122. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study
123. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
124. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
125. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
126. Budesonide controlled ileal release prolongs remission in Crohn's disease in Crohn's disease (CD): A pooled analysis
127. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
128. Efficacy of oral Pentasa 4 g/day in treatment of active Crohn's disease: A metaanalysis double-blind, placebo-controlled trials
129. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis
130. Double blind, placebo controlled trial of metronidazole in Crohn's disease
131. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
132. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin
133. Methotrexate for the treatment of Crohn's disease
134. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
135. A randomized controlled trial of CDP571, a humanized antibody to TNF alpha, in moderately to severely active Cronh's disease
136. A randomized, double-blind, placebo-controlled multicenter trial of the engineered human antibody to TNF (CDP 571) for steroid sparing and maintenance of remission in patients with Crohn's disease
137. Treatment of fistulizing Crohn's disease
138. Medical therapy to reduce postoperative Crohn's disease recurrence
139. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
140. Azathioprine for maintaining remission of Crohn's disease
141. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis
142. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients